Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.

Summary

HS-20105 is a novel antibody-drug conjugate (ADC) targeting Trop-2. This first-in-human trial is aimed to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics (PK), safety and preliminary anti-tumor activity of HS-20105 in patients with advanced solid tumors.

Timeline

Start

2024-03-01

Primary completion

2026-03

Completion

2027-03-01

Drugs

Indications